Eyes on May 2026: A month of durable therapies, a regulatory reversal, and rethought echanisms

May 2026 was a busy stretch for clinical and translational eye care. The month brought multi-year durability data for 2 very different approaches to inherited retinal disease (IRD), a regulatory turnaround that could reshape the wet age-related macular degeneration (AMD) market, a genuinely novel mechanism for treating the ocular surface, and a new entry in the long-running conversation about macular nutrition. Here is what stood out.

Durable data anchors gene and optogenetic therapy for retinitis pigmentosa

Retinitis pigmentosa (RP) has long offered patients little beyond low-vision aids, with photoreceptor loss treated as largely irreversible. Two presentations highlighted in the ARVO 2026 coverage (published May 5) reported 3-year outcomes for distinct biological strategies, and the recurring word was durability.

The first was MCO-010, an optogenetic gene therapy from Nanoscope Therapeutics that delivers a multi-characteristic opsin via intravitreal AAV2 to bipolar cells, aiming to restore light sensitivity by bypassing dead photoreceptors. Because it does not depend on a patient's specific mutation, the approach is described as disease-agnostic. In the RESTORE phase 2b/3 trial and its REMAIN extension, treated eyes showed best-corrected visual acuity gains corresponding to roughly 3 ETDRS lines, and those improvements were maintained out to week 152 with no treatment-related serious adverse events. Greater response was linked to evidence of transduction on fundus autofluorescence, baseline central subfield thickness above 100 µm, and disease duration under 30 years. In a companion release on the REMAIN data (May 15), the company framed the results as "durable and clinically meaningful" gains from a single injection.

The second program, DVC1-0401, took the opposite philosophical route: rather than restoring vision, this third-generation lentiviral vector expresses pigment epithelium-derived factor to slow degeneration through neuroprotection. In a small, genotype-independent phase 1/2a trial, treated eyes declined more slowly in both acuity and central retinal sensitivity than untreated fellow eyes, with no vector-related serious adverse events across 36 months. The investigators were appropriately cautious, noting that the single-arm design needs confirmation. Together, the 2 studies showed that "restore" and "protect" strategies can each post multi-year signals, though only the optogenetic program is advancing toward a biologics license application.

A regulatory turning point for ophthalmic bevacizumab in wet AMD

The most consequential regulatory news came late in the month. As reported in Ophthalmology Times' coverage of the FDA appeal, the agency granted Outlook Therapeutics' appeal following a Formal Dispute Resolution process with the Office of New Drugs, which concluded that substantial evidence of effectiveness had been established for bevacizumab-vikg (Lytenava) in neovascular AMD.

That decision reversed the trajectory set by a Complete Response Letter issued at the end of December 2025, clearing the way for the company to resubmit its application in June 2026. Because the filing is expected to be treated as a Class 1 resubmission, it would trigger a 60-day review, which puts a possible decision as early as August 2026. The stakes are practical rather than just procedural: an approved ophthalmic bevacizumab would be the first such formulation backed by FDA-reviewed manufacturing, labeling, and pharmacovigilance, offering retina specialists a regulated alternative to the off-label compounded bevacizumab many already use. The drug already carries marketing authorization in the European Union and the United Kingdom, with launches underway in Germany, Austria, and the UK, so the appeal essentially reactivates a US pathway that had stalled. If it clears, bevacizumab-vikg would join ranibizumab, aflibercept, faricimab, and brolucizumab in the approved anti-VEGF landscape, with potential downstream effects on payer and formulary decisions.

Rethinking dry eye: harnessing photosynthesis at the ocular surface

For sheer mechanistic novelty, nothing in May matched the dry eye research detailed in Ophthalmology Times' report on spinach-derived nanoparticles (May 15). A team at the National University of Singapore engineered plant-derived photosynthetic nanoparticles, dubbed LEAF, that let corneal cells generate the antioxidant cofactor NADPH when exposed to ordinary ambient light. The findings were published the same day in Cell.

The rationale starts with the disease's biology. Corneal inflammation drives reactive oxygen species that overwhelm the eye's own NADPH-dependent antioxidant systems, creating a self-amplifying loop of cellular injury. Existing approved therapies such as cyclosporine A (Restasis) and lifitegrast (Xiidra) work by dampening inflammation, but they carry cost and tolerability burdens that limit long-term adherence. LEAF is conceptually different: it is not a conventional drug but a biologically derived nanoparticle that installs working photosynthetic machinery into mammalian cells, an idea the authors compared to sea slugs that borrow algal chloroplasts to photosynthesize. In preclinical models, the eye drops reversed corneal damage to near-healthy levels within five days. The caveat is equally clear: this work is preclinical with no regulatory filing, but the prospect of a light-powered, non-pharmacologic ocular surface therapy is a striking departure from incremental anti-inflammatory drug development.

New options and lingering questions in macular nutrition

Closing out the month, Ophthalmology Times covered the US launch of Bausch + Lomb's PreserVision AREDS3 (May 19), an over-the-counter supplement that keeps the established AREDS2 micronutrient formula and adds a full B-vitamin complex spanning thiamin, riboflavin, niacin, pantothenic acid, B6, biotin, folate, and B12. The company says the addition was informed by a December 2025 narrative review in Ophthalmology and Therapy that synthesized more than 20 human studies covering roughly 30,000 individuals and that the new softgel achieves about twice the absorption of lutein and zeaxanthin compared with the prior formulation.

The biological rationale for B vitamins, tied to homocysteine metabolism and cellular energy pathways, is plausible, but the supporting evidence comes largely from observational data and select randomized signals rather than a dedicated AREDS3 formulation trial. The piece urged clinicians to counsel patients that this is a dietary supplement not evaluated by the FDA for disease claims and to treat the B-vitamin addition as hypothesis-generating until prospective, long-term data arrive. A confirmatory trial is reportedly in planning. It is a useful reminder that a new product on the shelf and a new standard of care are not the same thing.

Incremental gains in the hard problem of childhood glaucoma

Away from the device launches and regulatory headlines, the month also offered a window into pediatric glaucoma, a field where rare disease and surgically demanding anatomy make high-quality evidence genuinely difficult to generate. A Rising Star profile of Adam Jacobson, MD (May 23), of the Kellogg Eye Center at the University of Michigan, captured both the constraints and the progress. As Jacobson noted, randomized controlled trials are nearly impossible in a condition this uncommon, and the data simply are not as deep as in adults.

His work with Brenda L. Bohnsack, MD, PhD, tackles a persistent problem: glaucoma drainage devices tend to fail quickly in children, often within three to five years. In a retrospective series of 28 children (40 eyes), augmenting Ahmed glaucoma devices with Ologen, a biodegradable type I collagen matrix disc, significantly lowered both intraocular pressure and medication burden, with complete success in 55% of eyes and qualified success in 75%, alongside meaningful three- to five-year survival rates. The proposed mechanism is elegant: the disc reorganizes fibroblasts to blunt the aggressive scarring response that shortens device lifespan in young eyes.

The profile also flagged an intriguing clinical observation. Among extremely premature infants, the so-called micro-preemies born as early as roughly 22 to 23 weeks, Jacobson described two distinct presentations of apparent congenital glaucoma. One group followed the expected course and ultimately required surgery, while the other responded to topical drops, cleared their corneas, normalized their optic nerve cupping, and were eventually tapered off medication entirely, hinting at a possible distinct, self-limiting entity worth formally characterizing.

The throughline

Taken together, May 2026 traced a coherent arc across the specialty. The RP data pushed on durability, asking whether early functional gains hold up over years. The bevacizumab appeal was about access and the regulatory machinery that governs it. The Singapore work reimagined mechanism, treating the cornea as something that could be powered rather than merely medicated. The AREDS3 launch underscored the evidentiary standards that separate marketing from clinical proof. And the pediatric glaucoma profile was a reminder that in rare, surgically complex disease, progress often comes incrementally, one carefully studied cohort at a time. Different corners of the eye, different stages of development, but a shared insistence that durability, access, and rigorous evidence are what ultimately reach patients